Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
To assess the efficacy and safety of switching patients from bilateral latanoprost to bimatoprost in 1 eye while maintaining latanoprost in the fellow eye. This prospective, open-label, multicenter, uniocular (within-eye control) study was conducted from March 2005 to February 2007; 105 patients with glaucoma or ocular hypertension were enrolled. At baseline, patients using bilateral latanoprost were switched to bimatoprost treatment in 1 eye (study eye) and continued latanoprost treatment in the fellow eye (control eye). At 12 weeks, patients were offered bilateral bimatoprost for 12 additional weeks. At week 12, the mean difference in intraocular pressure (IOP) from baseline was -3.0 mm Hg in study eyes and -1.6 mm Hg in control eyes, which equates to a further -1.4 mm Hg (95% confidence limits: -1.9, -0.9) reduction in IOP in study eyes compared with control eyes (P<0.0001). Overall, 27% (28/104) more study eyes had > or = -2.5 mm Hg reduction in IOP than control eyes (P<0001). At week 24, the mean difference in IOP from baseline was -2.8 mm Hg for study eyes and for control eyes that had switched to bimatoprost. Conjunctival hyperemia occurred more frequently and was more severe in bimatoprost-treated eyes at week 12 than at baseline (P<0.001). No patients withdrew from treatment because of conjunctival hyperemia. Clinically, these data suggest that switching patients from latanoprost to bimatoprost may result in further improvement in IOP control.